2024-03-29T11:00:08Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02012470
2023-08-03T05:43:22Z
1642838163960:1642838338003
1642838403551:1642838407795
A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I
Fujii, Hideki
Shimizu, Mamoru
Miyagi, Takuya
Kunihiro, Marie
Tanaka, Reiko
Takahashi, Yoshiaki
Tanaka, Yuetsu
HTLV-I
NOG mice
neutralizing monoclonal antibody
envelope gp46
passive immunity
Although the number of human T-cell leukemia virus type-I (HTLV-I)-infected individuals in the world has been estimated at over 10 million, no prophylaxis vaccines against HTLV-I infection are available. In this study, we took a new approach for establishing the basis of protective vaccines against HTLV-I. We show here the potential of a passively administered HTLV-I neutralizing monoclonal antibody of rat origin (LAT-27) that recognizes epitopes consisting of the HTLV-I gp46 amino acids 191–196. LAT-27 completely blocked HTLV-I infection in vitro at a minimum concentration of 5 μg/mL. Neonatal rats born to mother rats pre-infused with LAT-27 were shown to have acquired a large quantity of LAT-27, and these newborns showed complete resistance against intraperitoneal infection with HTLV-I. On the other hand, when humanized immunodeficient mice were pre-infused intravenously with humanized LAT-27 (hu-LAT-27), all the mice completely resisted HTLV-I infection. These results indicate that hu-LAT-27 may have a potential for passive immunization against both horizontal and mother-to-child vertical infection with HTLV-I.
論文
http://purl.org/coar/resource_type/c_6501
MDPI
2016-02-03
VoR
http://hdl.handle.net/20.500.12000/46074
1999-4915
Viruses
2
8
eng
https://doi.org/10.3390/v8020041
https://doi.org/10.3390/v8020041
open access
Creative Commons Attribution 4.0
https://creativecommons.org/licenses/by/4.0/